- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00392509
ALD-301 for Critical Limb Ischemia, Randomized Trial (CLI-001)
A Phase I-II Randomized Autologous Bone Marrow Derived Aldehyde Dehydrogenase-Bright (ALDHbr) Cells Against Unfractionated Autologous Mononuclear Bone Marrow in Patients With Rutherford 4 or 5 Peripheral Arterial Occlusive Disease
Study Overview
Status
Intervention / Treatment
Detailed Description
Patients will be recruited who have critical limb ischemia with pain at rest. The study will select patients for treatment and follow them for three months after intervention. The treatment will consist of drawing about 2/3 of a cup of bone marrow from the patient's hip bone, then processing the collected bone marrow will be as follows:
- The test group's bone marrow will be processed and sorted to identify the aldehyde dehydrogenase bright ALDH-br stem and progenitor cells (ALD-301). These cells will be injected into the calf muscle of the patient in clinic.
- The control group will have the same amount of bone marrow collected but it will undergo a simpler process to isolate the mononuclear cells from the whole bone marrow, removing most of the red cells and granulocytes from cell preparation for injection.
The patients will be monitored for adverse events related to this process to determine the safety of the approach. They will also be tested at intervals during the study to compare baseline values of each patient with the post-treatment values of:
- ankle-brachial index of systolic blood pressure
- the transcutaneous oxygen measurements obtained from the skin of the treated leg
- the patient's perception of his/her quality of life as measured by two different, validated questionnaires
- Measurements of of heel/foot ulcers, if present, to monitor degree of healing if it occurs
- the patient's perception of his/her level of pain in the leg
The patients will receive a call at 6 months to report on additional life events following the study.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35211
- Cardiology PC
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
- Saint Joseph's Research Institute
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- University of Indiana at Indianapolis
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
-
Texas
-
Houston,, Texas, United States, 77030
- Texas Heart Institute, Stem Cell Center, 6770 Bertner, St Luke's Episcopal Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients 18 years of age or greater with atherosclerotic vascular disease that is viewed as not readily amenable to reconstructive surgery and Rutherford Category 4 ischemia (ischemic rest pain) and Rutherford Category 5 ischemia (ulceration or tissue necrosis) and by the judgment of their referring physician are not reasonable candidates for revascularization options of either percutaneous balloon angioplasty or a surgical revascularization.
- Objective evidence of severe peripheral arterial disease will include an ankle brachial index (ABI) of less than 0.5, or, in the case of patients who have vessels calcified and thereby "non-compressible" vessels metatarsal pulse volume recording (PVR) that is flat or barely pulsatile in the diseased limb on two consecutive examinations performed at least one week apart.
- Patients competent to give informed consent.
- No active malignant disease that could involve the bone marrow, or history of treatment of malignant disease that could have damaged the bone marrow.
- Before being accepted for the study the patient must be screened for human immunodeficiency virus, hepatitis B virus, hepatitis C virus, human transmissible spongiform encephalopathy, including Creutzfeldt-Jacob Disease, Treponema pallidum, and have a negative standard infectious disease panel including a CMV PCR test.
- Patients who are hemodynamically stable.
Exclusion Criteria:
- Patients with poorly controlled diabetes mellitus (HbA1C > 8%)
- Patients with renal insufficiency (creatinine > 2.5).
- Patients with evidence of infectious disease as determined by e. above or other medical findings.
- Pregnant women (women capable of childbearing must have a negative pregnancy test).
- Patients with cognitive impairments.
- Other comorbid disease that would be expected to result in less than one year life expectancy
- Past malignancy or history of chemotherapy or radiation affecting the bone marrow.
- History of inflammatory or progressively fibrotic conditions: .e.g., rheumatoid arthritis, systemic lupus erythematosis, vasculitic disorders, idiopathic pulmonary fibrosis, retroperitoneal fibrosis
- Infection as evidenced by WBC count of >15,000 and/or temperature >38 degrees C. Large area of cellulitis in the afflicted limb that in the opinion of the investigators would require the institution of antibiotics OR evidence of osteomyelitis corroborated by radiographic or scintigraphic examination
Cardiovascular conditions:
- Exercise limiting angina ( Canadian Cardiovascular Society Class 3 (Appendix 7);
- Congestive heart failure (New York Heart Association class 3 (Appendix 5);
- Unstable angina;
- Acute ST elevation myocardial infarction (MI) within 1month;
- Transient ischemic attack or stroke within 1 month;
- Severe valvular disease
- Patients with any history of organ transplants;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 2
Unfractionated Autologous Mononuclear Bone Marrow
|
Surgery
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
adverse events
Time Frame: 6 months
|
6 months
|
ankle-brachial systolic pressure index
Time Frame: 3 mo
|
3 mo
|
transcutaneous oxygen value (mm Torr)
Time Frame: 3 mo
|
3 mo
|
quality of life (questionnaires)
Time Frame: 3 mo
|
3 mo
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
size of lower extremity ulcer(s)
Time Frame: 3 mo
|
3 mo
|
peripheral nerve conduction exam
Time Frame: 3 mo
|
3 mo
|
level of pain at rest (questionnaire)
Time Frame: 3 mo
|
3 mo
|
limb clinical status
Time Frame: 3 mo
|
3 mo
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Emerson C Perin, M.D., Ph.D., Stem Cell Center, Texas Heart Institute, St Luke's Episcopal Hospital, 6770 Bertner , Suite 1020 Texas Medical Center,Houston, Texas 77030
- Principal Investigator: Robert Mitchell, MD, Duke University
- Principal Investigator: Michael Murphy, MD, University of Indiana at Indianapolis
- Principal Investigator: Nicolas Chronos, MD, Saint Joseph's Research Institute
- Principal Investigator: Farrell Mendelsohn, MD, Cardiology PC
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BB IND 12875
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Arterial Disease
-
University of NebraskaNot yet recruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | Peripheral Arterial Occlusive Disease | Peripheral Artery DiseaseUnited States
-
CID S.p.A.Meditrial Europe Ltd.Not yet recruitingPeripheral Arterial Occlusive Disease | Peripheral Artery DiseaseItaly
-
Marissa JarosinskiRecruitingPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Clopidogrel, Poor Metabolism of | Artery DiseaseUnited States
-
Stanford UniversityTerminatedPAD - Peripheral Arterial Disease | PVD- Peripheral Vascular DiseaseUnited States
-
Vascuros Medical Pte LtdNovella ClinicalUnknownPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery DiseaseSingapore, Belgium, Germany
-
Western Vascular Institute, IrelandRecruitingPeripheral Arterial Occlusive DiseaseIreland
-
Jena University HospitalAngioDroid s.r.l., Bologna (Italy)CompletedPeripheral Arterial Occlusive DiseaseGermany
-
Seoul National University HospitalAstellas Pharma Korea, Inc.CompletedPeripheral Arterial Occlusive DiseaseKorea, Republic of
-
Heidelberg UniversityTerminatedPeripheral Arterial Occlusive DiseaseGermany
-
Johann Wolfgang Goethe University HospitalSuspendedPeripheral Arterial Occlusive DiseaseGermany
Clinical Trials on ALDH-br bone marrow cells vs. mononuclear bone marrow cells
-
Chinese PLA General HospitalUnknownLeft Ventricular Dysfunction | Chronic Myocardial Ischemia | Old Myocardial InfarctionChina
-
IRCCS San RaffaeleSuspended
-
Andalusian Initiative for Advanced Therapies -...Iniciativa Andaluza en Terapias AvanzadasCompletedChronic Myocardial IschemiaSpain
-
TotipotentSC Scientific Product Pvt. Ltd.Thermogenesis Corp.CompletedCritical Limb IschemiaIndia
-
Andalusian Network for Design and Translation of...Carlos III Health InstituteCompletedDiabetic Foot | Peripheral Vascular DiseasesSpain
-
Vinmec Healthcare SystemCompleted
-
The University of Texas Health Science Center,...Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedIschemic StrokeUnited States
-
Hebei Medical UniversityUnknownDiabetes | Lower Limb IschemiaChina